A Phase I/IB Study of Ipilimumab or Nivolumab in Patients With Relapsed Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation

ANALYTE_TYPE - Analyte Type (phv00487732.v1.p1)
BODY_SITE - Body site where sample was collected (phv00487731.v1.p1)
CONSENT - Consent group as determined by DAC (phv00487725.v1.p1)
HISTOLOGICAL_TYPE - Cell or tissue type or subtype of sample (phv00487734.v1.p1)
IS_TUMOR - Tumor status (phv00487733.v1.p1)
SAMPLE_ID - Sample ID (phv00487729.v1.p1)
SAMPLE_ID - Sample ID (phv00487728.v1.p1)
SEQUENCING_CENTER - Name of the center which conducted sequencing (phv00487736.v1.p1)
SUBJECT_ID - Subject ID (phv00487724.v1.p1)
SUBJECT_ID - Subject ID (phv00487727.v1.p1)
TIME_OF_SAMPLING - Time point of sample collection (phv00487730.v1.p1)
TUMOR_TREATMENT - Type of tumor treatment for sample (phv00487735.v1.p1)